Visiongain Report Looks at Opportunities Within the $6.3bn Anti-Obesity Drugs Market

Visiongain Report Looks at Opportunities Within the $6.3bn Anti-Obesity Drugs Market

PR Newswire

LONDON, December 5, 2018

LONDON, December 5, 2018 /PRNewswire/ --

Global Anti-Obesity Drugs Market Forecast 2018-2028 

Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs 

     (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1% from 2017 to 2022. In 2017, the prescription drugs submarket held 96% of the global anti-obesity drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 119 tables and 139 figures- all unavailable elsewhere.

The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

Global Anti-obesity Drugs Market forecast from 2018-2028

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:
• Incretion mimetics/GLP-1 agonists
• SNDRIs
• Lipase Inhibitors
• Serotonin receptor agonists
• Sympathomimetic-GABA receptor agonists
• Sympathomimetics

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy:
• Long-term Drugs
• Short-term Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs:
• Innovator
• Generic Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC:
• Prescription Drugs
• OTC

• This report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs:
• Saxenda
• Contrave/Mysimba
• Belviq
• Qysmia
• Xenical
• Alli

• This report provides individual revenue forecasts from 2018-2028 for these regional and national markets:
• US
Japan
• EU5: Germany, France, Spain, Italy, UK
• BRIC: Brazil, Russia, China, India
• RoW

Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs

• Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market:
• Eisai/Arena
• GlaxoSmithKline (GSK)
• Novo Nordisk
• Orexigen/Takeda
• Roche
• Teva
• Vivus

• This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.

• This report gives an overview of pricing and reimbursement in the US and EU.

• This report provides a SWOT Analysis of the global anti-obesity drugs market.

Visiongain's study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-anti-obesity-drugs-market-forecast-2018-2028/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

ADial Pharmaceuticals
AEMPS
AIFA
HAS
Akrimax Pharmaceuticals
American Medical Association
Arena Pharmaceuticals
AstraZeneca
Biophytis
Boehringer Ingelheim
Boston Therapeutics
Diasome
Eisai
EMEA
Empros Pharma
FDA
G-BA
GenePreDiT
GlaxoSmithKline (GSK)
Hanmi
Ildong Pharmaceuticals
Intarcia Therapeutics
Ionis Pharmaceuticals
Janssen Pharmaceuticals
KT&G Life Sciences
KVK Tech
Kwang Dong
Medivation
Medlab Clinical
Neothetics
NGM Biopharmaceuticals
NICE
SMC
Novartis
Novo Nordisk
OPKO Health
Orexigen
Rhythm Pharmaceuticals
Roche
Saniona
Shionogi & Co., Ltd
Takeda
Teva
Valeant Pharmaceuticals
Virtici
Vivus
World Health Organization (WHO)
Xenetic Biosciences
Zafgen

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Voltar noticias em Inglês